GenSight Biologics secures a €35 million credit facility from the European Investment Bank to support the launch of LUMEVOQ® in Europe

GenSight Biologics Reports Cash Position and Revenues as of September 30, 2022

GenSight Biologics to Present at Upcoming Industry and Investor Conferences

GenSight Biologics Reports Interim Financial Results for the First Half of 2022

GenSight Biologics Announces the Filing of its 2021 Universal Registration Document

GenSight Biologics Reports Cash Position and Revenues as of March 31, 2022

GenSight Biologics Reports Full Year 2021 Consolidated Financial Results

GenSight Biologics Announces its 2022 Financial Calendar

Chardan 5th Annual Genetic Medicines Conference – virtual

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ASRS, ESGCT and Several Investor and Industry Meetings in October